Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Medical School

Harvard Medical School

2013, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

Boston, MA

Fellowship

Boston Children's Hospital/Dana-Farber Cancer Institute

Boston, MA

Professional History

Dr. David Shulman studies novel therapies and biomarkers for advanced pediatric solid tumors within the Dana-Farber Experimental Therapeutics Program. In addition to early phase clinical trials, Dr. Shulman also studies circulating tumor DNA as a potential tool to improve the ways in which we treat patients with bone tumors,

Publications

  1. Emerging Role of Blood-based Biomarkers in Sarcomas. Hematol Oncol Clin North Am. 2025 May 22. View Abstract

  2. Case 14-2025: A 29-Year-Old Woman with Peritonsillar Swelling and Bleeding. N Engl J Med. 2025 May 15; 392(19):1954-1964. View Abstract

  3. Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. medRxiv. 2025 Jan 20. View Abstract

  4. Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. J Natl Compr Canc Netw. 2024 Dec 27; 23(1). View Abstract

  5. Targeted-Agent Continual Reassessment Method: A Novel Bayesian Enrichment Design for Phase I Trials of Molecularly Targeted Therapies. JCO Precis Oncol. 2024 Dec; 8:e2400360. View Abstract

  6. Statistical Fragility of Findings From Randomized Phase 3 Trials in Pediatric Oncology. Cancer Med. 2024 Dec; 13(24):e70356. View Abstract

  7. Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group report. J Natl Cancer Inst. 2024 Oct 01; 116(10):1664-1674. View Abstract

  8. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Med. 2024 Apr; 13(8):e7154. View Abstract

  9. Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatr Blood Cancer. 2023 Dec; 70(12):e30681. View Abstract

  10. Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. JCO Clin Cancer Inform. 2023 09; 7:e2300104. View Abstract

  11. Evaluation of prevalence and outcomes of serial tyrosine kinase inhibitor use in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30652. View Abstract

  12. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023 07; 12(14):15207-15216. View Abstract

  13. Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. Br J Cancer. 2022 12; 127(12):2220-2226. View Abstract

  14. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6(1):65. View Abstract

  15. Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clin Cancer Res. 2022 06 13; 28(12):2579-2586. View Abstract

  16. Derivation and validation of a risk classification tree for patients with synovial sarcoma. Cancer Med. 2023 01; 12(1):170-178. View Abstract

  17. Rapid and highly sensitive approach for multiplexed somatic fusion detection. Mod Pathol. 2022 08; 35(8):1022-1033. View Abstract

  18. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021 12 01; 39(34):3822-3828. View Abstract

  19. Facial Paralysis From Post-transplant Lymphoproliferative Disorder. Otol Neurotol. 2021 06 01; 42(5):e605-e608. View Abstract

  20. Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. J Clin Med. 2021 Apr 14; 10(8). View Abstract

  21. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Apr; 10(7):2310-2318. View Abstract

  22. Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. Pediatr Blood Cancer. 2021 03; 68(3):e28834. View Abstract

  23. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2021 02; 68(2):e28807. View Abstract

  24. Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatr Blood Cancer. 2020 11; 67(11):e28694. View Abstract

  25. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020 09; 9(18):6658-6666. View Abstract

  26. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract

  27. Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med. 2020 07; 9(13):4495-4500. View Abstract

  28. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View Abstract

  29. The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020 Apr; 22(2):189-197. View Abstract

  30. Using Liquid Biopsy in the Treatment of Patient with OS. Adv Exp Med Biol. 2020; 1257:95-105. View Abstract

  31. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019 11; 66(11):e27938. View Abstract

  32. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. View Abstract

  33. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019 05; 112:49-56. View Abstract

  34. Winning the RACE: Expanding pediatric cancer drug approvals. Pediatr Blood Cancer. 2019 08; 66(8):e27705. View Abstract

  35. Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. Pediatr Transplant. 2019 05; 23(3):e13384. View Abstract

  36. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019 05; 66(5):e27595. View Abstract

  37. A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568. View Abstract

  38. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. View Abstract

  39. Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964. View Abstract

  40. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors. J Pediatr Hematol Oncol. 2016 11; 38(8):610-614. View Abstract

  41. Implementation and Validation of Telepathology Triage at Cancer Referral Center in Rural Rwanda. J Glob Oncol. 2016 Apr; 2(2):76-82. View Abstract

  42. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 May; 21(5):913-9. View Abstract

  43. Diagnosis of cancer in rural Rwanda: early outcomes of a phased approach to implement anatomic pathology services in resource-limited settings. Am J Clin Pathol. 2014 Oct; 142(4):541-5. View Abstract

  44. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23. View Abstract

  45. Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 2001 Nov; 86(11):5379-82. View Abstract

  46. Fentanyl anesthesia in familial dysautonomia. Anesth Analg. 1985 Jan; 64(1):72-6. View Abstract
BESbswy